---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096188"
form_type: "8-K"
ticker: "TKNO"
cik: "0001850902"
company_name: "Alpha Teknova, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:49:59.425410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M

## Summary
- Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.
- Net loss $5.4M ($0.13/share) vs $7.2M prior year; Adjusted EBITDA negative $2.6M.
- Gross margin fell to 29.2% from 43.9% due to lower Clinical Solutions revenue and higher overhead.
- Raised $15.4M equity in July 2024; cash $18.6M, debt $12.1M; confirms free cash outflow <$18M for FY.
- Clinical customers up 26% to 43; launched Express-Tek and RUO+ offerings.

## SEC filing metadata
- accession: 0000950170-24-096188
- form_type: 8-K
- ticker: TKNO
- cik: 0001850902
- company_name: Alpha Teknova, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/0000950170-24-096188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/tkno-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096188
- JSON: https://secwatch.observer/filing/0000950170-24-096188.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.